Mr Bill Edge

KANDO id: 21527

Bio

Held a number of senior positions in industry before moving into venture capital in 1985 as a director of Grosvenor Venture Managers. Grosvenor was acquired by Mercury Asset Management (MAM) in 1994, since when he has acted as a consultant to NVM and to Merlin Biosciences Limited. Director of the Merlin Fund and the Merlin Biosciences Fund, two specialist biotechnology funds founded by Professor Sir Christopher Evans, and a director of Alizyme plc.


Career


NVM Private Equity Ltd

Independent private equity firm
Email: [email protected]

Education